Indications

HR-Positive and HER2-Negative Advanced or Metastatic Breast Cancer (see Breast Cancer)

Clinical Efficacy

• xxx

---

Pharmacology

Specific Inhibitor of Cyclin-Dependent Kinases 4/6 (CDK4/6)

• xxx

Metabolism

• xxx

---

Administration

• xxx

Dose Adjustment

• Hepatic: xxx
• Renal: xxx

Use in Pregnancy (see Pregnancy)

• xxx

Use in Lactation

• xxx

---

Adverse Effects

Pulmonary Adverse Effects

Pneumonitis/Interstitial Lung Disease (ILD) (see Pneumonia and Interstitial Lung Disease)

• Epidemiology
  • Case Report of Pneumonitis in Patient with Breast Cancer (with Bone Metastases) (Breast Care (Basel). 2020) [MEDLINE]
    • Pneumonitis Occurred 3 mos After initiation of Palbociclib
    • Patient Improved with Withdrawal of Palbociclib and Treatment with Steroids
  • Reports of Interstitial Lung Disease from Japanese Adverse Drug Event Report (JADER) Database and FDA Adverse Event Reporting System (FAERS) (Cancer Rep-Hoboken, 2021) [MEDLINE]
    • Treatment with Abemaciclib and Palbociclib were Associated with a Potential Complication of Interstitial Lung Disease (Regardless of Age)

---

References

• Can CDK4/6 inhibitors cause fatal lung injury? Expert Rev Anticancer Ther. 2019 Nov;19(11):917-919. doi: 10.1080/14737140.2019.1674651 [MEDLINE]
• New Drugs, Old Toxicities: Pneumonitis Related to Palbociclib – A Case Report. Breast Care (Basel). 2020 Oct;15(5):548-552. doi: 10.1159/000504618 [MEDLINE]
• CDK 4/6 inhibitor induced lung injury: a case report and review of literature. Ecancermedicalscience. 2021 Jun 7;15:1245. doi: 10.3332/ecancer.2021.1245. eCollection 2021 [MEDLINE]
• Evaluation of potential complication of interstitial lung disease with abemaciclib and palbociclib treatments. Cancer Rep (Hoboken). 2021 May 3;e1402. doi: 10.1002/cnr2.1402 [MEDLINE]